CD8A and melanoma: Cis-spliced peptides can carry cancer-specific mutations50,51, and in the peripheral blood of melanoma patients, CD8+ T cells and cytotoxic T lymphocytes (CTLs) recognize melanoma-associated cis-spliced epitopes52,53.